Science

Addition of sintilimab to pemetrexed and platinum improved progression-free survival

Addition of sintilimab to pemetrexed and platinum improved progression-free survival

The interim analysis of ORIENT-11, a phase III double-blind randomized trial has shown a nearly two-fold increase in progression-free survival with addition of sintilimab to chemotherapy in patients with advanced or metastatic non-squamous non-small cell lung cancer without EGFR or ALK genomic aberrations, according to research data presented today at the International Association for the Study of Lung Cancer Virtual Presidential Symposium.

Read More…….
EurekAlert!, the online, global news service operated by AAAS, the science society,